Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear.

The article reports on the study presented by Edwin van Cutsem at the American Society of Clinical Oncology, which shows the result of the Crystal trial, a randomized phase III study of irinotecan and 5-flouroucaril (5-FU)/folinic acid (FOLFIRI) with or without cetuximab as front-line therapy in 1217 patients with metastatic colorectal carcinoma. Result suggests that a statistically significant difference in favor of cetuximab was seen in KRAS wild-type patients for progression-free survival.